Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY-Reference-Cited by-同舟云学术

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Published:2018-10-31 Issue:1 Volume:94 Page:46-54
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Hehlmann Rüdiger¹^ORCID,Cortes Jorge E.²^ORCID,Zyczynski Teresa³,Gambacorti-Passerini Carlo⁴,Goldberg Stuart L.⁵^ORCID,Mauro Michael J.⁶,Michallet Mauricette⁷,Simonsson Bengt⁸,Williams Loretta A.⁹,Gajavelli Srikanth³,DeGutis Irene³,Sen Ginny P.¹⁰,Paquette Ron L.¹¹

Affiliation:

1. Universität Heidelberg and ELN-Foundation; Weinheim Germany

2. The University of Texas; MD Anderson Cancer Center; Houston Texas

3. Bristol-Myers Squibb; Princeton New Jersey

4. University of Milano Bicocca; San Gerardo Hospital; Monza Italy

5. John Theurer Cancer Center; Hackensack University Medical Center; Hackensack New Jersey

6. Memorial Sloan-Kettering Cancer Center; New York New York

7. Centre Hospitalier Lyon-Sud; Pierre-Bénite France

8. Uppsala Universitet; Uppsala Sweden

9. The University of Texas MD Anderson Cancer Center; Houston Texas

10. ICON Clinical Research LLC; South San Francisco California

11. UCLA Medical Centre; Los Angeles California

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25306/fullpdf

Reference38 articles.

1. Chronic myeloid leukemia: what every practitioner needs to know in 2017;Khoury;American Society of Clinical Oncology educational book American Society of Clinical Oncology Meeting,2017

2. NCCN Guidelines Chronic Myelogenous Leukemia Version 1;National Comprehensive Cancer Network (NCCN);J Natl Compr Canc Netw,2016

3. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

4. Long-term outcomes of imatinib treatment for chronic myeloid leukemia;Hochhaus;N Engl J Med,2017

5. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants;Hehlmann;Leukemia,2017

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia;New England Journal of Medicine;2024-09-12

2. Exploring treatment decision-making in chronic myeloid leukemia in chronic phase;Frontiers in Oncology;2024-07-01

3. Real World Outcomes with Treatment Free Remission in Chronic Myeloid Leukemia-Experience from a Tertiary Care Cancer Centre;Indian Journal of Hematology and Blood Transfusion;2024-05-13

4. Challenges in management of older patients with chronic myeloid leukemia;Leukemia & Lymphoma;2024-04-23

5. A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia;Expert Opinion on Drug Safety;2024-04